Thursday, March 25, 2010

Responsibility to Disseminate Clinical Research and Educate Key Target Groups

Clinical research data from Clinical Trial Phases 1, 2, 3 and 4 provides the most up to date scientific objectives and prescribing information for an approved drug. Pharma must educate all key groups who have a vested interest in the well being of the patient throughout the life cycle of the drug. Dissemination of information to at least the following primary constituents is a must.
  • Health Care Physicians
  • Health Care Provider's - A provider's responsibility is to provide health care that is effective, affordable and satisfactory to as many people/patients as possible. When new products have entered the market, health care providers are primarily concerned with clinical research that demonstrates information pertaining to patient tolerability, safety and effectiveness. Clinical trial research is paramount for adequate development of "friendly and patient focused" health plans. In today's medical culture where the paradigm has shifted from the physician to the patient, health care plan companies see the need to become more patient-oriented. This presents huge opportunities for pharma companies to work with in-house and external clinical researchers and spearhead additional types of clinical research.
  • Buyers, Consumers, Distributors
  • Key Opinion Leaders
  • Sales and Marketing
  • FDA.

No comments:

Post a Comment